PROFOUNDA, INC.

Impavido (miltefosine) is now available in the USA directly from Profounda for the treatment of leishmania.

Profounda licenses Impavido from Knight Therapeutics for marketing into the US. Leishmaniasis is a parasitic disease that is found in...

MONTREAL, Canada, September 25, 2015 – Knight Therapeutics Inc. (TSX: GUD) (“Knight”), through one of its wholly-owned subsidiaries,...

Profounda will be introducing Rhinase Soothing Nasal Mist and Lubricating Nasal Gel at the Convenient Care Association Meeting held in...

Profounda Plans to launch Rhinase in Fall 2015 Profounda Inc. (private) today announced the pre-market preparation for the planned launch...

Profounda Inc. (private) today announced the signing of a license agreement with a major pharmaceutical company for a line of OTC...

Starting September 1st, Profounda will be located at 5790 Hoffner Avenue, Suite 507, Orlando, Florida 32822-4824

Profounda received additional private equity funding for development of Profounda's products. Profounda works with third party vendors...

Profounda completes series A2 round of financing which will allow for future development of its pipeline products. new specialty...

Profounda completes ex-US licensing outlicensing rights for a product in development in exchange for upfront milestone and downstream...